Superworth10x Genomics shares outstanding TXG
Diluted shares outstanding, averaged over each quarter, from 2018.
- Latest quarter, to Jun 30, 2026
- 130M
- On a year earlier
- +4.4%
- more shares
10x Genomics had 130M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 4.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 127.1M | +5% |
| FY2024 | 121.6M | +3% |
| FY2023 | 118.6M | +3% |
| FY2022 | 114.8M | +3% |
| FY2021 | 111.9M | +4% |
| FY2020 | 107.4M | +12% |
| FY2019 | 96M | +586% |
| FY2018 | 14M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 130M | +4% | |
| Q1 FY26 | 128.3M | +5% | |
| Q4 FY25 | 127.1M | +5% | |
| Q3 FY25 | 125.5M | +4% | |
| Q2 FY25 | 124.5M | +4% | |
| Q1 FY25 | 122.6M | +3% | |
| Q4 FY24 | 121.6M | +3% | |
| Q3 FY24 | 120.7M | +3% | |
| Q2 FY24 | 120.1M | +3% | |
| Q1 FY24 | 119.4M | +3% | |
| Q4 FY23 | 118.6M | +3% | |
| Q3 FY23 | 117.7M | +3% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on 10x Genomics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.